The obesity field is one of the most dynamic areas within life science today. BioStock meets Pila Pharma’s CEO, Gustav Hanghøj Gram, for a discussion about the company’s work for a new tablet treatment in obesity and the key impressions from this year’s Obesity Week. The conversation covers the interest in Pila Pharma’s unique TRPV1 inhibitor XEN-D0501, how the oral candidate may differentiate itself from current treatments, and how the company views the increasing big pharma appetite, competition and developments in the field. We also get an update on the ongoing collaboration with Gubra and the milestones that lie ahead.